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In the most recent confidential enquiry into maternal 
deaths, medical disorders in pregnancy are listed 
as one of the top five causes of maternal mortality 
in South Africa (SA),[1] with cardiac disease (CD) 
being a major contributor (Fig. 1). In developed 
countries, such as the UK and the Netherlands, heart disease is the 
most common cause of indirect mortality, with surgically corrected 
congenital heart disease (CHD) comprising the greater proportion of 
this group. Because of childhood surgical intervention, most women 
with CHD reach childbearing age.[2,3] In SA and other developing 
countries, acquired heart disease such as rheumatic heart disease, 
hypertensive disorders of pregnancy[4,5] and cardiomyopathies 
contribute the largest number of patients, although CHD remains 
significantly represented.[3,6,7] 
Evaluation of cardiac disease in 
pregnancy
The care of pregnant patients with CD requires special attention to 
diagnostics, treatment and continuous follow-up. Conducting a systematic, 
accurate and realistic risk assessment for potential maternal and fetal 
complications and anticipated adverse outcomes, both during pregnancy 
and postpartum, is vital to the success and safety of the pregnancy.[8] 
When evaluating the impact of CD in pregnancy, it is important to 
mention the physiological adaptions occurring in a normal pregnancy. 
With regard to the circulatory system, the primary event is peripheral 
vasodilatation, which results in a decrease in peripheral vascular resistance. 
Due to this effect the cardiac output (CO) increases by approximately 
40%, which is mainly achieved by an increase in stroke volume (SV) and 
is secondarily due to an increase in pulse rate (PR). These variables are 
expressed by the equation CO = SV × PR. It is not uncommon for the PR 
to increase by up to 20 beats/min. The systemic blood volume increases 
by approximately 50% antenatally and by a further 50% at delivery, 
when a massive autotransfusion of blood from the involuting uterus into 
the general circulation occurs. In general, pregnancy is a well-adapted, 
physiologically altered state, provided that every system (including the 
cardiovascular system) remains healthy. However, in the presence of CD, 
the circulatory changes may adversely affect maternal survival, morbidity 
and perinatal outcome.[9] The close interaction of the cardiovascular system 
and the placenta has provided evidence for a cardioplacental syndrome 
that has been described previously.[10] 
Diagnosing cardiac disease
History and examination
Many disorders can be identified by a clinical examination and a 
patient’s history, but in the majority, if not all cases, an echocardiogram 
is required to confirm clinical suspicions. 
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Medical disorders in pregnancy are one of the top five causes of maternal mortality in South Africa (SA), cardiac disease (CD) being 
the main contributor to this group. In developed countries, surgically corrected congenital heart disease (CHD) comprises the greater 
proportion of maternal deaths from CD. In SA and other developing countries, acquired heart disease such as rheumatic heart disease and 
cardiomyopathies are the major causes, although CHD remains significantly represented.
Both congenital and acquired cardiac lesions may present for the first time during pregnancy. CD may also occur for the first time during 
or after pregnancy, e.g. peripartum cardiomyopathy. The risk to both the mother and the fetus increases exponentially with the complexity 
of the underlying disease. Generally, the ability to tolerate a pregnancy is related to: (i) the haemodynamic significance of any lesion; (ii) the 
functional class – New York Heart Association classes III and IV have poorer outcomes; (iii) the presence of cyanosis; and (iv) the presence 
of pulmonary hypertension. While the ideal time to assess these factors is before conception, women frequently present when already 
pregnant. This review discusses risk assessment and management of CD in pregnant women and the role of a combined cardiology and 
obstetric clinic. 
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Fig. 1. Maternal mortality in South Africa.[1]
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Both congenital and acquired cardiac lesions may present for the 
first time during pregnancy. In many cases the history is unclear and 
documentation of previous surgical procedures unavailable. CD may 
also occur for the first time during pregnancy or the postpartum 
period, e.g. in peripartum cardiomyopathy. 
In all cases, a detailed family history is especially important and 
may highlight the risk of a congenital lesion, as well as potentially 
fatal conditions such as arrhythmias and sudden death syndromes. 
Symptoms such as increased shortness of breath, decreased effort 
tolerance, orthopnoea, paroxysmal nocturnal dyspnoea, syncope, 
palpitations and chest pain are all potential indicators of CD. 
However, in pregnant women it may be impossible to distinguish 
such symptoms from those which commonly occur during a normal 
pregnancy, i.e. shortness of breath, fatigue and decreased effort 
tolerance. In addition, the cardiovascular examination of a healthy 
pregnant woman may well reveal peripheral oedema, a raised PR and 
a physiological murmur. 
Critical evaluation of the symptoms described in the history 
will enable the clinician to distinguish pathology from normal 
physiological changes. For example, a woman who cannot complete 
daily tasks owing to worsening shortness of breath, can be categorised 
as a New York Heart Association (NYHA) class III or IV patient, 
and if she has trouble sleeping it would be cause for concern. On the 
other hand, a woman who maintains her usual functional level with 
the typical physiological breathlessness of pregnancy most noticeable 
at rest and decreasing with exertion, would be unlikely to have 
cardiovascular pathology. 
A resting tachycardia, a pathological murmur and/or signs of 
cardiac failure are findings that would require urgent investigation. 
Table 1 summarises the physiological adaptations of the cardiovascular 
system during pregnancy.
Special investigations
Investigations such as an electrocardiogram (ECG), a 24-hour heart 
rate and rhythm (Holter ECG) recording or an echocardiogram are 
technically more difficult, particularly in advanced pregnancy, but 
should be performed if indicated. Table 2 summarises the normal 
adaptations found on a 12-lead ECG of a pregnant patient.
The transthoracic echocardiogram is the most important screening 
and diagnostic tool in identifying structural lesions and assessing 
cardiac function. An additional benefit in pregnancy is that it does 
not expose the patient to radiation and can be repeated as often as 
required. However, an echocardiogram is technically more difficult to 
perform in a pregnant woman owing to the gravid abdomen, breast 
engorgement and rotation of the heart. 
A 24-hour Holter ECG should be used if there is clinical suspicion 
of significant arrhythmias or if the patient complains of symptoms 
such as prolonged palpitations or syncope. More sophisticated 
devices, such as loop recorders, have been inserted into a select group 
of patients who are at high risk of potentially fatal arrhythmias. 
Assessment of risk 
Once a diagnosis has been made and cardiac function evaluated, 
assessment of the potential effect of the pregnancy on the CD, as well 
as the effect of this condition on the pregnancy, should be documented. 
Arrangements should be made for the delivery and follow-up during 
the antenatal and postpartum periods. An optimal time for these plans 
to be implemented would be before conception, as this would allow for 
a baseline assessment of cardiac function and provide an opportunity 
for the relevant counselling. Indicated interventions can be performed 
prior to conception, thus avoiding fetal exposure to ionising radiation 
and procedural risks.[3] In the case of a familial condition, or if there 
is a risk of inheritance (e.g. congenital cardiac lesion), it may also 
be relevant to refer the patient to and include a medical geneticist 
during the pre-pregnancy counselling sessions.[3] Once the patient has 
expressed a wish to conceive, cardiac function should specifically be 
evaluated and adjustments made to medications if necessary. 
Risk scores 
There are various risk scoring systems available to assist in the 
counselling of patients with CD in their reproductive years. Risk 
scores are population-dependent and any given study examining 
risk should therefore have an adequate prevalence within the sample 
population of a specific lesion or clinical scenario to be able to 
evaluate the risk meaningfully.
In broad terms, the ability to tolerate a pregnancy is related to the 
following:[11]
• haemodynamic significance of any lesion
• initial functional class
• presence of cyanosis  
• presence of pulmonary hypertension.
To date, the World Health Organization (WHO)’s risk assessment 
classification is the most accurate, comprising four categories of 
severity (Table 3):[11] 
• WHO I: No increased risk of mortality, mild increased risk of 
morbidity – low risk.
• WHO II: Small increased risk of mortality, moderate increased risk 
of morbidity – medium risk.
• WHO III: Significantly increased risk of mortality and morbidity 
– high risk.
• WHO IV: Extremely high risk of mortality or severe morbidity – 
pregnancy contraindicated.
Table 1. Physiological adaptations of the cardiovascular 
system in pregnancy 
Normal history Normal physical examination 
Palpitations Tachycardia
Fatigue
Lateral and upwards displacement of the 
apex beat
Dyspnoea Loud, often split first and split second heart 
sound
Reduced exercise 
tolerance 
Mid-systolic murmur at the left base (flow 
murmur-hyperdynamic circulation) 
Continuous murmur (venous increased 
mammary flow) 
Peripheral oedema
Table 2. Normal adaptations found on a 12-lead 
electrocardiogram (ECG) of a pregnant patient 
Left axis deviation of the heart (the heart is rotated to the left in 
normal pregnancy) 
Transient ST-segment and T-wave changes (inverted T wave) 
Atrial ectopic beats 
Ventricular ectopic beats 
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Other published risk classifications include the cardiac disease in 
pregnancy (CARPREG) scale, which allocates a point for each of the 
following (Table 4):[3]
The total score is interpreted as follows:
• 0 points = 5% risk of maternal complications
• 1 point  = 27% 
• >1 point = 75%. 
In addition to the above, the following independent predictors may 
be included: 
• any prior cardiac event (e.g. congestive cardiac failure or 
arrhythmia) 
• baseline NYHA >II
• use of cardiac medication
• ejection fraction <40%.
Referral pathways 
The risk to the mother and fetus increases exponentially with the 
complexity of the underlying disease.[12] Based on the risk categories 
described above, a referral algorithm (Fig. 2) has been developed by 
our unit, which provides a guideline to assist in the correct referral of 
pregnant patients with suspected or known CD to a multidisciplinary 
combined cardiology and obstetric clinic.
During consultations, a team of cardiologists and obstetricians will 
make a detailed assessment, based on the following criteria: 
What is the present cardiac function? 
The cardiac function of a pregnant woman needs to be assessed by applying 
the NYHA functional class, and any current prescribed medication 
required to maintain this functional class needs to be documented. The 
physical examination must include blood pressure, heart rate and an 
overall clinical examination, including an ECG. If the patient has an 
abnormal clinical examination or ECG, an echocardiogram is indicated.
What is the severity of the lesion (according to the WHO scale) and 
its impact on cardiac function?
A patient with a large ventricular septum defect may, for example, have 
a severe left-to-right shunt that puts the right heart under increased 
strain when the volume expansion of pregnancy commences. If the 
pressure in the right heart and pulmonary vessels increases to that of 
the left heart, the result is a left-to-right shunt, leading to cyanosis. 
Another example is the consequence of severe mitral regurgitation, 
which may lead to an enlarged left atrium, clot formation and atrial 
fibrillation. 
Table 3. World Health Organization (WHO) risk assessment 
classification of cardiac disease in pregnancy
WHO I
Uncomplicated small or mild disease
Pulmonary stenosis
Patent ductus arteriosus
Mitral valve prolapse
 Successfully repaired simple lesions (atrial or ventricular septal 
defect, patent ductus arteriosus, anomalous pulmonary venous 
drainage) 
Atrial or ventricular ectopic beats, isolated
WHO II or III
WHO II (if otherwise well and uncomplicated) 
Unoperated atrial or ventricular septal defect
Repaired tetralogy of Fallot
Most arrhythmias
WHO II - III (depending on individual) 
Mild left ventricular impairment
Hypertrophic cardiomyopathy
 Native or tissue valvular heart disease not considered WHO I or 
IV
Marfan syndrome without aortic dilatation
Aorta <45 mm in aortic disease associated with a bicuspid valve
Repaired coarctation
WHO III
Mechanical valve 
Systemic right ventricle
Fontan circulation
Cyanotic heart disease (unrepaired) 
Other complex congenital heart disease 
Aortic dilatation 40 - 45 mm in Marfan syndrome 
 Aortic dilatation 45 - 50 mm in aortic dissection with bicuspid 
aortic valve
WHO IV (pregnancy contraindicated) 
Pulmonary arterial hypertension of any cause
 Severe systemic ventricular dysfunction (LVEF <30%, NYHA 
III - IV) 
 Previous peripartum cardiomyopathy with any residual 
impairment of left ventricular function
Severe mitral stenosis, severe symptomatic aortic stenosis 
Marfan syndrome with aorta dilated  >45 mm
 Aortic dilatation >50 mm in aortic disease associated with 
bicuspid aortic valve
Native severe coarctation 
LVEF = left ventricular ejection fraction; NYHA = New York Heart Association.
Table 4. Cardiac disease in pregnancy (CARPREG) scale[3] 
Prior cardiac event
Baseline NYHA >II or cyanosis 
Left heart obstruction: MS <2 cm, AO <1.5 cm, LV outflow gradient 
>30 mmHg
LV dysfunction (EF <40%) 
NYHA = New York Heart Association; MS = mitral stenosis; AO = aorta; LV = left 
ventricular; EF = ejection fraction.
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What is the risk to the fetus?
There are certain risks to the fetus in terms of inheritance, growth 
restriction, use of medication, and preterm delivery. 
What is expected to occur during pregnancy, and how will this be 
managed? 
During pregnancy there is often a decrease in effort tolerance and 
an increase in shortness of breath, requiring the administration 
of a diuretic, e.g. hydrochlorothiazide or furosemide. Patients 
may also experience palpitations, which can be controlled by a 
beta-blocker. 
The WHO classification can also be used to guide the frequency of 
visits to specialised clinics:
• WHO I: Limit visits to once during the pregnancy. 
• WHO II: Follow-up every trimester. 
• WHO III: Monthly or bi-monthly review by a multidisciplinary 
team of cardiologists and obstetricians.
• WHO IV: Advise against pregnancy or, in some cases, recommend 
early termination. If the patient continues the pregnancy, 
bi-monthly review is advised. 
At each visit to the multidisciplinary clinic, it is important to assess 
for symptoms and warning signs of deteriorating cardiac function:
On history:  
• Change in NYHA class or NYHA >II. (Change in effort tolerance 
or ability to function with regard to daily domestic tasks.) 
• More medication is required to maintain current functional status. 
• New symptoms, e.g. chest pain, have developed.
On examination: 
• Increased PR (either a resting tachycardia or a raise after mild exertion, 
such as walking from waiting area into the examination room).
• Worsening oedema.
• Change in the cardiac murmur or signs of cardiac failure, such as 
Primary and secondary maternal care
Modied WHO
Classication I
Modied WHO
Classication II
Previously diagnosed
hypertension, diabetes, 
morbid obesity (BMI >35)
Successfully repaired simple
lesions
Uncomplicated, small or mild
mitral valve prolapse,
pulmonary stenosis
Palpitations − no dizziness
Modied WHO
Classication III - IV
Unoperated ASD and VSD
Repaired tetralogy of Fallot and 
coarctation
Arrhythmias and dizziness
Mild left ventricular impairment (EF
>45%, NYHA FC II) due to newly
diagnosed PPCM or HT heart
failure
Previously diagnosed RHD with 
murmurs and/or recently assessed
asymptomatic mechanical valve
Mechanical valve and symptoms
Complex congenital or cyanotic
heart disease
Previously diagnosed peripartum
cardiomyopathy
Pulmonary hypertension any cause
Severe ventricular impairment 
(EF <45%, NYHA FC >II)
Aortic dilatation >45 mm (bicuspid
AV, Marfan)
Tertiary care maternal
facility
Tests: BP, ECG, echocardiogram
and assess for murmurs
Non-urgent referral
Urgent referral
Follow up with maternity
service
Joint cardiac-obstetric-anaesthetic CDM team
Consulting with: paediatric cardiologist,
endocrinologist, radiologist, HIV specialist and others
Postpartum referral to main cardiac
clinic if indicated for management
and possible cardiothoracic surgery
Fig. 2. Referral algorithm for suspected and previously known cardiovascular disease in maternity (BP = blood pressure; BMI = body mass index; ECG = 
electrocardiogram; ASD = atrial septal defect; VSD = ventricular septal defect; EF = ejection fraction; NYHA FC = New York Heart Association Functional 
Class; PPCM = peripartum cardiomyopathy; HT = hypertension; RHD = rheumatic heart disease; AV = aortic valve; CDM = cardiovascular disease in 
maternity).
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crepitations at the lung bases or raised jugular venous pressure.
• Signs of infection (in the case of a replaced valve or valvular CD).
Delivery
Spontaneous vaginal delivery is recommended in pregnant women 
with CD. In most cases, the decision for a surgical delivery is based on 
obstetric indications. A surgical (or assisted) vaginal delivery may be 
indicated to reduce maternal Valsalva exertion in the second stage of 
labour. In all cases, the mode of delivery should be planned before the 
onset of labour and additional anaesthetic advice obtained in cases 
where an epidural procedure is indicated (e.g. mitral regurgitation) 
or an emergency caesarean section is anticipated.
Anticoagulation in women with 
mechanical valves
Pregnancy is a state of physiological thrombophylia. The risk of 
valve thrombosis is increased in pregnancy and anticoagulation 
therapy must be continued. Warfarin is well documented to be the 
most effective anticoagulant and is best for the mother, giving the 
lowest risk of thrombosis; however, it crosses the placenta and is 
associated with adverse fetal outcomes, including teratogenesis (nasal 
hypoplasia and epiphyseal stippling), miscarriage, stillbirth and 
intracranial bleeding. Low molecular weight heparin (LMWH) has 
no risk to the fetus, but a higher risk of maternal thrombosis.
The risk of teratogenesis of warfarin is from 6 to 12 weeks’ gestation 
and has been documented as between 3.4% and 6%[13,14] and as high as 
11% (C Elliott – unpublished MMed data), and the risk increases with 
increased dosages of warfarin >5 mg/day. At 6 weeks the patient needs 
to be hospitalised and warfarin replaced with heparin. Continuous 
intravenous infusion of unfractionated heparin is recommended, 
keeping the partial thromboplastin time (PTT) ≥2.5 × control value. The 
use of therapeutic LMWH is still controversial owing to the high rate of 
valve thrombosis and the difficulty of monitoring therapeutic dosage 
and efficacy. If used, it is essential to monitor antifactor Xa levels at least 
weekly to ensure a 4-hour peak level of 0.8 - 1.2 U/mL. Low-dose aspirin 
should be used along with LMWH at a dose of 75 mg/day. 
Warfarin can be restarted after 12 weeks’ gestation, ensuring the 
international normalised ratio (INR) is 2.5 - 3.5. Warfarin needs to 
be discontinued again at 36 weeks, the patient re-hospitalised, and 
intravenous heparin restarted. It should be discontinued 4 - 6 hours 
before a planned delivery, or if the patient is in established labour. 
Heparin infusion should be restarted 4 - 6 hours after delivery if there 
are no bleeding complications and if no regional anaesthetic has been 
given, and warfarin re-initiated between day 3 and 7 postpartum.[15] 
The fetus
Adverse neonatal and perinatal outcomes are more common in pregnant 
women with CD. There is a relationship between the complexity and 
severity of the CD and fetal and neonatal complications.[16,17] In general, 
the greater the risk posed by the mother’s CD, the greater the risk to the 
fetus. 
It is well documented that babies born to mothers with CD are 
more likely to suffer one of the following complications: 
• preterm delivery (this includes both iatrogenic and spontaneous 
preterm delivery)
• respiratory distress syndrome 
• small for gestational age and low birth weight 
• fetal growth restriction  
• intraventricular haemorrhage 
• neonatal death and stillbirth. 
Maternal predictors of adverse neonatal outcome have been listed 
as:[9,11] 
• baseline NYHA >II or cyanosis
• maternal left heart obstruction
• smoking during pregnancy
• multiple gestation
• use of oral anticoagulants
• mechanical valve prosthesis.
The potential adverse effect of maternal CD on neonatal outcome 
is increased if there are concurrent obstetric risk factors, including 
maternal age >35 years,[9] although the mechanisms behind this are 
not fully understood. There are various explanations for the increased 
rate of neonatal complications, e.g. cyanosis is associated with fetal 
growth retardation. A decrease in maternal oxygen saturation is 
directly related to birth weight and perinatal mortality. Adverse 
perinatal outcome may be explained by the decrease in uteroplacental 
blood flow resulting from haemodynamic compromise in patients with 
CD.[9,16] Placental insufficiency plays a role in preterm delivery, fetal 
growth restriction and perinatal loss in patients with a compromised 
functional class.[9] Fetal cardiac contractility and output are adversely 
affected by hypoxaemia resulting from uteroplacental insufficiency.[9]
The association between the abovementioned neonatal 
complications and cognitive and neurodevelopmental delay has been 
demonstrated. This should be included in the discussion with the 
patient during the pregnancy, or at the pre-conception visit. 
Conclusion
Given the importance of CD in pregnancy and the impact on maternal 
and fetal mortality and morbidity, there is a clear need for structured 
assessment, appropriate referral and surveillance by a multidisciplinary 
team. The correct and early identification of pregnancy-specific 
conditions such as peripartum cardiomyopathy cannot be over-
emphasised. Pre-conception diagnosis, counselling and risk assessment 
are ideal but, if this is not possible, correct diagnosis as early as possible 
in pregnancy is absolutely vital to improve maternal and fetal outcome. 
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